Eylea’s Global Net Sales Increase 20 Percent in Q1-2018

May 4, 2018: By Jon Swedien

Net sales for Eylea (aflibercept) across the globe rose to $1.61 billion in Q1-2018, up 20 percent compared with Q1-2017, Regeneron reported May 3.

Eylea’s net sales in the US in Q1-2018 were $984 million, a 15 percent increase compared with the same quarter from the prior year, Regeneron reported.

Bayer commercializes Eylea outside the US, where the anti-VEGF’s net sales for Q1-2018 were $624 million, a 29 percent increase compared with Q1-2017, Regeneron said.

Regeneron recognized nearly $248 million in Q1-2018 from its share of net profit from Eylea sales outside the US, the company said.

Eylea gained approval in March from China’s FDA for the treatment of visual impairment due to diabetic macular edema (DME).

In addition, Eylea in March met its 24-week primary endpoint in a Phase III trial evaluating the anti-VEGF as a treatment for moderately severe to severe nonproliferative diabetic retinopathy.

Regeneron’s total revenues for the quarter were $1.5 billion, a 15 percent increase compared with Q1-2017, the Tarrytown, New York, company reported.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023